Kristina Masson
About Kristina Masson
Kristina Masson: Co-Founder and EVP at Acrivon
Kristina Masson holds multiple significant roles at Acrivon, including Co-Founder, Executive Vice President of Business Operations, Site Head, and Director. She has been instrumental in establishing and leading Acrivon's phosphoproteomic hub and early drug programs leveraging the company's AP3 platform. Her leadership has been key in driving forward the company's strategic initiatives and operational capacities.
Kristina Masson: Expertise in Cancer Biology and Therapeutics
Kristina Masson boasts extensive expertise in cancer biology, predictive biomarkers, and the development of novel therapeutics. Her background includes developing sophisticated assays for novel therapeutics and creating automated high-throughput drug screening approaches focused on synthetic lethality in cancer. This specialized knowledge has been crucial to her roles in various high-impact pharmaceutical and biotech initiatives.
Kristina Masson’s Educational Background
Kristina Masson completed an Executive MBA from the Massachusetts Institute of Technology Sloan School of Management. She also holds a M.Sc. and a Ph.D. from Lund University in Sweden. Additionally, she completed a Post-Doctoral Fellowship at the Broad Institute of MIT and Harvard, contributing to her deep expertise in cancer biology and drug development.
Professional Roles and Contributions by Kristina Masson
Before her current roles, Kristina Masson co-founded and led OncoSignature as President and CEO before its acquisition by Acrivon. She was also a cross-functional team lead at Merrimack Pharmaceuticals. Kristina's work at the Broad Institute of MIT and Harvard included developing sophisticated assays and high-throughput drug screening approaches. These roles underline her extensive experience in the pharmaceutical and biotech industries.
Kristina Masson: Board Membership at Aqilion AB
Kristina Masson serves as a member of the Board of Directors for Aqilion AB. Her role on the board leverages her extensive background in cancer biology and therapeutics to help guide the strategic directions of the company. Her participation underscores her influence and recognition in the pharmaceutical and biotechnology sectors.